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Leber’s hereditary optic neuropathy (LHON) was the first maternally inherited disease to be associated with point mutations in
mitochondrial DNA and is now considered the most prevalent mitochondrial disorder. The pathology is characterized by selective loss of
ganglion cells in the retina leading to central vision loss and optic atrophy, prevalently in young males. The pathogenic mtDNA point
mutations for LHON affect complex I with the double effect of lowering the ATP synthesis driven by complex I substrates and increasing
oxidative stress chronically.
In this review, we first consider the biochemical changes associated with the proton-translocating NADH-quinone oxidoreductase of
mitochondria in cybrid cells carrying the most common LHON mutations. However, the LHON cybrid bioenergetic dysfunction is essentially
compensated under normal conditions, i.e. in glucose medium, but is unrevealed by stressful conditions such as growing cybrids in glucose
free/galactose medium, which forces cells to rely only on respiratory chain for ATP synthesis. In fact, the second part of this review deals
with the investigation of LHON cybrid death pathway in galactose medium. The parallel marked changes in antioxidant enzymes, during the
time-course of galactose experiments, also reveal a relevant role played by oxidative stress.
The LHON cybrid model sheds light on the complex interplay amongst the different levels of biochemical consequences deriving from
complex I mutations in determining neurodegeneration in LHON, and suggests an unsuspected role of bioenergetics in shaping cell death
pathways.
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1. Leber’s hereditary optic neuropathy (LHON): a permanent severe loss of central vision is the usual endpointcomplex I disease
LHON is an inherited form of acute or subacute loss of
central vision affecting predominantly young males [1]. The
rapid loss of central vision in one eye is usually painless and
followed by similar involvement of the other eye. Visual
acuity reaches stable residual values at or below 20/200
within a few months and visual field defect is characterized
by a large centro-cecal absolute scotoma. Optic atrophy with0005-2728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2004.05.009
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E-mail address: carelli@neuro.unibo.it (V. Carelli).of the disease. This is reflected at the histopathological level
by a striking loss of retinal ganglion cells (RGCs) and
atrophy of the optic nerve with severe diffuse demyelin-
ation. A complete loss of central fibers with various degrees
of axonal sparing in the periphery is observed by light
microscopy. Larger axon profiles are selectively spared,
immersed in the reactive gliotic tissue. Wide variability in
myelin thickness characterizes the spared fibers at the
ultrastructural level, some axons being almost denuded of
myelin sheath. Most of the demyelinated fibers showed
mitochondrial accumulation, sometimes completely filling
the axonal profile.
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identification of pathogenic mtDNA point mutations, the
three at positions 11778/ND4, 3460/ND1, and 14484/ND6
being the most common worldwide [2–6]. More recently, an
array of further rare but truly pathogenic mtDNA point
mutations has been described (see Ref. [1] for an updated
list), and they all affect different subunits of complex I, the
ND6 being a well-recognized hot spot. In most LHON
families the mtDNA pathogenic mutation affects all the
individuals on the maternal line in a homoplasmic fashion
(100% of the mtDNA molecules are mutant); however, not
all maternally related individuals develop LHON. Thus, the
mtDNA mutation is a necessary but not sufficient condition
to determine the pathology and the existence of further
genetic determinants, such as nuclear modifying genes, has
been largely hypothesized [7] and debated [8]. The variabil-
ity in penetrance observed in LHON families may also be
due to environmental factors, which may act as triggers of
the pathology, and tobacco smoking and alcohol consump-
tion are the most likely risk factors [9].2. Biochemical features of complex I dysfunction and
bioenergetic consequences of LHON mutations
The proton-pumping NADH:ubiquinone oxidoreductase,
also known as complex I, is the entry point for electrons into
the respiratory chains of many bacteria and mitochondria of
most eukaryotes [10,11]. It couples electron transfer with the
translocation of protons across the membrane, thus contrib-Fig. 1. Complex I model (adaputing to the proton motive force essential for energy-con-
suming processes. The current knowledge about human
complex I indicates that it is built up by the co-ordinated
expression and assemblage of 46 different subunit proteins
[12], 39 being encoded by the nuclear DNA and 7 bymtDNA.
The available three-dimensional structure of the enzyme
reveals a characteristic L shape [10], with the short arm
embedded in the inner mitochondrial membrane and the long
arm projecting out of the membrane into the mitochondrial
matrix (Fig. 1). The seven mtDNA-encoded subunits of
complex I (ND1 to ND6, and ND4L) belong all to the
membrane embedded domain, the short arm of the L. The
amino acid changes induced by the three most common
LHON mutations are listed in Table 1.
The biochemical effect of LHON pathogenic mutations
has been studied for over a decade and still remains quite
controversial (see for discussion the reviews by Brown [13],
Howell [14], and Carelli et al. [1]) With the exception of the
3460/ND1 mutation, which consistently decreases the elec-
tron transport activity of complex I, the other LHON
mutations induce only modest or subtle changes in measur-
able aspects of complex I function (Table 1). However, all
LHON mutations clearly induce a complex I-dependent
impairment of mitochondrial respiration.
The initial series of our biochemical investigations on
LHON-associated complex I mutations [15–18] failed to
show a significant reduction of complex I activity with the
11778/ND4 and 14484/ND6 mutations, although this reduc-
tion was evident with the 3460/ND1 mutation. These find-
ings were similar to those reported by others [1,13,14].ted from Refs. [10,11]).
Table 1
Biochemical features of the most common pathogenic mutations in LHON
nt position mtDNA gene Amino acid Protein domain Complex I electron transport activity
G3460A ND1 A 52 T (moderately conserved) extramembrane loop on the negative
side of the membrane
reduced (60–80%)
G11778A ND4 R 340 H (highly conserved) transmembrane helix close to the
negative side of the membrane
normal or slightly reduced (0–25%)
T14484C ND6 M 64 V (low conserved) central part of a transmembrane helix normal
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carrying the 11778/ND4 and 3460/ND1 mutations, and to a
lesser extent the 14484/ND6 mutation, had a decreased
sensitivity to rotenone, a powerful complex I inhibitor that
acts as an antagonist of Q intermediates [15–18]. Rotenone
affects the binding of semiquinone intermediates and of the
quinol product in complex I. We interpreted these changes
in rotenone sensitivity as suggestive of an altered stability of
the semiquinone intermediates formed during the catalytic
cycle of complex I. The latter terminates with the release of
a quinol product derived from controlled dismutation of the
semiquinones.
We also evaluated the sensitivity of complex I activity to
product inhibitors such as quinols and myxothiazol and
found that both the 14484/ND6 and 11778/ND4 LHON
mutations induced an increased sensitivity of complex I to
myxothiazol and nonyl-benzoquinol [1,18], by analogy with
what previously reported in cell lines carrying the rare
LHON/dystonia/Leigh 14459/ND6 mutation [19]. A prod-
uct inhibition was also reported for the 3460/ND1 mutation
[20]. Thus, alterations in the affinity for quinol products, as
well as resistance to the inhibitory effect of rotenone,
consistently suggested that LHON mutations affect the
interaction of complex I with the Q substrate [1,13–18].
Based on our results, we originally proposed that both a
partial decrease of net energy production and a slight chronic
increase of oxidative stress may result from complex I
dysfunction due to the mtDNA point mutation pathogeneti-
cally associated with LHON [15]. Subsequent studies were
undertaken in ours and in other laboratories to evaluate the
bioenergetic consequences of the LHON mutations.
Considering the metabolic flux control theory [21], which
defines the control that every single step in a pathway has
over the global flux of that pathway, the impairment of
complex I might result in a variably impaired respiration rate
and ultimately in different efficiencies of ATP synthesis [22].
The most extensive study on the respiration of lymphoblast
and cybrid mitochondria carrying one of three LHON
common mutations reached the conclusion that the 3460/
ND1 and 11778/ND4 mutations consistently decreased com-
plex I-driven respiration of 20–28% and 30–36%, respec-
tively, whereas the 14484/ND6 mutation induced a much
milder defect, quantified in a 10–15% decreased respiration
[23]. However, the authors of this study did not assess the
ATP synthesis rate with direct measurements to definitively
state whether bioenergetics per se is defective and whether
ATP availability to the cell is the primary event causingLHON. Another study, limited to the 11778/ND4 mutation,
reported that the energy charge, an index of energy avail-
ability in cells, was not decreased in lymphocytes from
LHON patients [24].
The issue of ATP synthesis and total ATP cellular content
in LHON has been partially addressed in a few studies
[20,25,26], and it has now been systematically investigated
in our laboratory using the cybrid cell model, expanding to
all the common LHON mutations and considering the
possible compensatory mechanisms operated by complex
I-independent substrates (Baracca et al., 2004, submitted for
publication). Combining our results and others’, we can now
state that the complex I-driven ATP synthesis is severely
affected with all three common LHON mutations. However,
there is also evidence that cells may effectively compensate,
mainly through ATP synthesis sustained by alternative path-
ways (through glycolysis and complex II/glycerol 3-phos-
phate dehydrogenase), in most human tissues. This set of
results on cells, either primary cultures from patients or
constructed cybrids, fits with the in vivo results obtained
using the 31P magnetic resonance spectroscopy (MRS) in
LHON patients, indicating a defective ATP synthesis in
skeletal muscle and/or brain [27,28].
Taken all into consideration, it is likely that besides the
bioenergetic deficit, other molecular mechanisms contribute
to the clinical onset of LHON. Impaired re-oxidation of
NADH which may occur in LHON cells would result in
increased [NADH]/[NAD+] ratio, which induces per se
decreased pH and increases synthesis of lactate, further
lowering the pH. This scenario may exert possible secondary
effects on metabolism, particularly when a high-energy
demand occurs, and glycolysis rate is increased in highly
energy demanding cells. Decreased pH might also synergis-
tically affect the redox centres of the respiratory chain,
further sustaining reactive oxygen species (ROS) overpro-
duction, as initially proposed [15], and recently shown to
occur in neuronal LHON cybrids [29].3. Cell death in LHON
It is well established that cells with defects of mitochon-
drial respiration are able to keep up the energy charge and
maintain normal growth rate in glucose containing media.
However, severe growth impairment and increased rate of
cell death occur when glucose in the growth medium is
replaced by galactose [30]. Under this condition, the slow
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cient for the cells to synthesize the bulk of ATP requirement
by glycolysis, and cells are forced to rely on respiratory chain
for ATP synthesis. Impairment of cell growth in galactose
medium has also been reported in cybrids bearing LHON
mutations [31]. Furthermore, we have recently reported that
incubation of LHON cybrids, but not of 143B.TK parental
cell line or of control cybrids, in galactose medium caused
cell death characterized by the typical hallmarks of apoptosis,
such as changes in nuclear morphology, chromatin conden-
sation and fragmentation of chromosomal DNA [32]. The
occurrence of a significant release of cytochrome c into the
cytosol clearly indicated a mitochondria-dependent cell death
pathway [32]. Increased sensitivity to cell death has also been
reported in the same LHON cybrid clones after treatment with
Fas, a well-known activator of the Fas ligand death receptor
pathway [33]. Given that the only relevant difference be-
tween LHON cybrids and control cybrids is the mtDNA
carrying the LHON pathogenic mutations, it is reasonable to
suggest that alteration in complex I structure or function may
result in the increased sensitivity to apoptotic cell death.
The hypothesis that a bioenergetic defect plays a critical
role in the pathophysiology of LHON has been strengthened
by our recent findings showing that the total cellular ATP
content of LHON cybrids, which is not significantly differ-
ent from controls in glucose medium, dramatically de-Fig. 2. Apoptotic pathways dcreased during the early times of incubation in galactose
medium. Indeed, ATP levels were reduced in all LHON
cybrid clones to approximately 30–50% after 3-h incubation
and to less than 10% after 24 h, whereas the ATP content of
the parental 143B cell line was not affected [34].
The inability of LHON cybrids to maintain their ATP
content during incubation in galactose medium is likely to
shape the pathway of cell death. In fact, it is well known that
different types of programmed cell death can be triggered by
mitochondria. In general, the efflux of cytochrome c from
these organelles is a pivotal event in the classical apoptotic
death, since it drives the assembly in the cytoplasm of the
apoptosome, a high molecular weight caspase-activating
complex. In fact, binding of cytochrome c to Apaf-1 pro-
motes its oligomerization, and recruitment of caspase-9 into a
multimeric Apaf-1–caspase-9 complex, which results in
caspase-9 activation. Caspase-9, in turn, directly processes
and activates the effector caspase-3 and -7 [35,36]. Notice-
ably, cleavage of inhibitor of caspase-activated deoxyribo-
nuclease (I-CAD) by caspase-3 causes CAD release, which
enters the nucleus to trigger both chromosomal DNA frag-
mentation and chromatin condensation [37,38]. The scheme
shown in Fig. 2 summarizes the pathway of caspase-mediated
apoptotic cell death.
Despite we reported a significant release of cytochrome c
from mitochondria in LHON cybrids [32], we have foundriven by mitochondria.
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pendent. In fact, no activation of DEVDase activity or
cleavage of procaspase-3 by Western blot could be deter-
mined [34]. Furthermore, pretreatment with the pan-cas-
pase-inhibitor z-VAD.fmk (100 AM) was unable to increase
the viability of cells incubated in galactose medium, where-
as it completely abolished the caspase-3 mediated cell death
triggered by staurosporine (Zanna et al., 2004 submitted for
publication). Given that both cytochrome c and ATP are
required for the assembly of apoptosome and subsequent
activation of caspase-9 and -3, it is likely that the drastic
reduction of ATP levels would impair the formation of the
oligomeric complex and consequently the activation of the
caspases cascade.
The presence of nuclear fragmentation in the absence of
caspase activation suggests the possibility of alternative
pathways of cell death [39]. One of these pathways is that
mediated by apoptosis inducing factor (AIF) and endonu-
clease G (EndoG), two apoptogenic factors present in the
mitochondrial intermembrane space that translocate to the
nucleus upon induction of apoptosis (see also Fig. 2). Both
EndoG and AIF have been reported to cause nuclear DNA
cleavage and fragmentation [40,41]. Studies are in progress
to assess whether these apoptogenic factors are also released
from mitochondria during the metabolic stress-induced
death of LHON cybrids.
The galactose model developed with LHON cybrids may
be extremely helpful, in the absence of a faithful and reliable
animal model for this disease, to simulate the pathogenic
cascade which may occur in vivo during the acute phase of
the pathological process when RGCs rapidly undergo a
massive wave of cell death. This model may be instrumental
to test rescue strategies that may form the basis for phar-
macological neuroprotection.4. LHON mutations and ROS
One important mechanism by which a defective mito-
chondrial respiratory chain may lead to cell damage and to
final commitment to apoptotic death is the overproduction of
ROS, which are common byproducts of oxidative reactions
occurring within the mitochondria. A major site of ROS
production (superoxide) at the respiratory chain level is
complex I [42]. Superoxide is rapidly converted to H2O2
by superoxide dismutase (SOD), and H2O2 in the presence of
reduced transition metals, such as Fe2 +, may either undergo
further reduction to a very reactive and toxic hydroxyl
radical through Fenton reaction, or be detoxified by several
lines of antioxidant defenses: catalase, glutathione and
glutathione cycling enzymes peroxydase (GPx) and reduc-
tase (GRH), scavenging molecules like peroxiredoxins,
vitamins A, C, and E or even the ambivalent coenzyme Q,
itself a possible culprit of ROS production.
ROS overproduction has been frequently reported in
cells harboring mtDNA pathogenic mutations [43,44],particularly when complex I dysfunction is implicated
[45,46] like in the recently established model of xenomi-
tochondrial cybrids [47,48]. A role for ROS in the path-
ogenesis of LHON has been initially proposed [15], and
mounting evidence of their involvement is now being
accumulated [29,49,50].
We also investigated ROS production in our collection
of LHON cybrids. Basal ROS production in cybrids har-
boring the three most common LHON pathogenic muta-
tions was modestly increased (Ref. [51]), or even
undistinguishable from controls [29]. There are indications
that the antioxidant defenses are activated, but still suffi-
cient to balance the subtle mitochondrial dysfunction. This
was demonstrated by the slight decrease in GSH content
and by the changes in SOD expression [51], compatible
with normal cell viability in nonselective conditions [52]. A
drastic change occurs when cells are stressed or under
increased metabolic demand. Under such conditions, ROS
production sensibly increases, antioxidant defenses col-
lapse, growth capacity declines, and cell death with the
hallmarks of apoptosis takes place (Refs. [32,53], Floreani
et al., submitted for publication).
The direct measurement of ROS may be tricky, and the
methods currently available all have some drawback. Keep-
ing this caveat in mind, a significant increase in ROS
generation has been indeed observed in NT2 neuronal
differentiated LHON cybrids carrying the 11778/ND4 and
3460/ND1 mutations [29]. This finding was confirmed
using a different detection method (dichlorofluoroscein) in
osteosarcoma cybrids carrying the 11778/ND4, 3460/ND1,
or the 14484 LHON mutations (Ref. [53]).
We are currently investigating soluble and enzymatic
antioxidant defenses in LHON cybrids grown either in
glucose rich medium, a condition in which cybrids rely
mostly on anaerobic metabolism for energy production [54],
or in glucose-free/galactose supplemented medium, where
cybrids are forced to rely upon the respiratory chain for ATP
synthesis. In glucose medium, the soluble antioxidant
defenses of cybrids are not different between LHON and
controls, whereas GRH and GPx activities were lower in
LHON cybrids carrying the 3460 and the 11778 mutations.
Since cybrids with LHON mutations and controls all share
an identical nuclear genome, the observed changes are
epigenetic, and most likely are the result of a posttransla-
tional inactivation caused by increased chronic ROS pro-
duction. These features become rapidly significant in LHON
cybrids during the time course experiments in galactose
medium (Floreani et al., submitted for publication). Thus,
we have evidence that drastic changes in the mitochondrial
antioxidant enzymatic machinery occur under the stressful
conditions imposed by the galactose model, suggesting a
possible burst of oxidative stress, which may be implicated
in the apoptotic cell death observed in LHON cybrids under
these conditions [29].
We need to mention a further interesting implication of
the chronic ROS overproduction associated with the LHON
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cell line, from which cybrids are derived, was recently
found to express the EAAT1/GLAST glutamate transporter
and the glutamate uptake was significantly reduced in all
LHON cybrids compared with control cybrid [54]. This
reduction strongly correlated, in a mutation-specific fashion,
with the degree of enhanced mitochondrial production of
ROS [55]. This observation may become relevant in the
context of the inner retina where the Muller cells, which
prevent RGCs from excitotoxicity, carry the EAAT1 as the
major source of glutamate removal.5. Conclusions and perspectives
The biochemical effect of LHON mutations revealed to
be complex and not univocally interpreted [1,13,14]. The
interplay of bioenergetics and oxidative stress with ana-
tomo-physiological tissue-specific features may determine
unusual consequences on cell viability, and influence the
specific pathways of neuronal cell death. RGCs, the target
tissue in LHON, are functionally skewed with high-energy
demand in the initial unmyelinated portion of the axons,
while the retrobulbar portion of the nerve, which is mye-
linated and action potentials are saltatory, has a lower
energy requirement [1]. Therefore, high numbers of mito-
chondrial population characterize the first portion, whereas
only a few docked mitochondria under nodes of Ranvier are
present in the retrobulbar part of the nerve [56]. The axonal
transport of mitochondria, a process fueled by mitochondrial
ATP, and mitochondrial distribution in axons seem a crucial
step for the correct function of the system [57]. Thus, any
bioenergetic defect may potentially be harmful either on
action potential conduction and/or mitochondrial transport
and cell viability [1].
On the other hand, excess of oxidative stress may result
damaging on different cell types, like oligodendrocytes
providing the myelination of RGCs axons [1]. A chronic
impairment of myelin turnover may worsen axonal function
and metabolism. The acute loss of visual function in LHON
patients suggests that once a threshold is crossed a rapid wave
of cell death occurs, possibly due to the triggering of
apoptotic pathways, which selectively affect the RGCs via-
bility. Our cellular model in galactose may resemble this last
series of molecular events, and we showed how a rapid loss of
the bioenergetic cell balance under these circumstances may
become relevant in directing the cell death modality, with the
possible contribution of an oxidative stress burst.
The LHON cybrid cell model in galactose will be
instrumental to rescue experiments, testing each of the
different aspects of the pathophysiology, i.e. correcting the
complex I-driven defect of ATP synthesis and/or buffering
ROS production and/or interfering with the apoptotic path-
way. Preliminary results in our laboratory are encouraging
towards the design of appropriate therapies rescuing cell
death in our cell model.Besides, the results obtained from such studies on cells
from LHON patients will provide valuable information on
fundamental aspects of bioenergetics in eukaryotes. Detailed
biochemical investigations of the altered complex I carrying
the amino acid replacements induced by the LHON mtDNA
mutations will certainly shed further light on the role of ND
subunits, of the specific amino acid positions and of their
chemico-physical characteristics, all relevant information for
the enzyme structure and function. At present, this achieve-
ment cannot be reached in other ways, and it allows also a
comparative analysis of the eukaryotic amino acid changes
with those in bacteria, easily obtainable by means of site-
directed mutagenesis.Acknowledgements
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